S100A8 and esophageal squamous cell carcinoma: Additionally, ESCC patients with high S100A8/A9 expression exhibited lower recurrence rates (18% vs. 46%) and lower post-chemotherapy recurrence rates (29% vs. 58%) compared to the low-expression group (Fig. 4g; Supplementary Fig. 4f), highlighting its potential as a marker to guide postoperative chemotherapy strategies in ESCC.